Elranatamab monotherapy or with daratumumab for previously treated relapsed or refractory multiple myeloma

Elranatamab, alone or in combination with daratumumab, is in clinical development for the treatment of relapsed or refractory multiple myeloma (MM). MM is a type of bone marrow cancer that is characterised by an abundance of abnormal immune cells, known as plasma cells, in the bone marrow. In the early stages, MM may not cause any symptoms, however it eventually causes a wide range of problems such as persistent bone pain, tiredness, weakness, shortness of breath, repeated infections, unusual bleeding, and kidney problems. In relapsed or refractory MM (RRMM), the patient has gone into complete or partial remission but then the disease has returned (relapsed) or stopped responding to treatment (refractory). Outcomes for patients with disease progression is poor, therefore there is a need to develop new treatment options for RRMM.